NASDAQ: SXTP60 Degrees Pharmaceuticals Inc Stock
$4.16+0.31 (+8.05%)
Updated Feb 6, 2026
SXTP Price
$4.16
Fair Value Price
N/A
Market Cap
$4.40M
52 Week Low
$1.36
52 Week High
$17.68
P/E
-4.95x
P/B
0.99x
P/S
4.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.23M
Earnings
-$7.97M
Gross Margin
22.4%
Operating Margin
-647.06%
Profit Margin
-688.2%
Debt to Equity
0.53
Operating Cash Flow
-$7M
Beta
-0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SXTP Overview
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SXTP's potential to beat the market
- SXTP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SXTP
RankedUnranked of 483
RankedUnranked of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.38 | A | |
| $165.50 | A | |
| $16.09 | A |
Be the first to know about important SXTP news, forecast changes, insider trades & much more!
SXTP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SXTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SXTP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SXTP is good value based on its book value relative to its share price (0.99x), compared to the US Biotechnology industry average (5.16x)
P/B vs Industry Valuation
SXTP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SXTP due diligence checks available for Premium users.
Valuation
SXTP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.95x
Industry
234.95x
Market
42.26x
SXTP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
5.16x
SXTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SXTP's financial health
Profit margin
Revenue
$528.6k
Net Income
-$2.3M
Profit Margin
-462.2%
SXTP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SXTP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7M
Liabilities
$2.3M
Debt to equity
0.53
SXTP's short-term assets ($6.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTP's short-term assets ($6.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
-$25.5k
Financing
$4.3M
SXTP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SXTP vs Biotech Stocks
60 Degrees Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.